Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
NRIX
NRIX | US
16.57
USD-0.06
-0.36%
NRIX | US
About NRIX
Sector
Healthcare
Industry
Biotechnology
Earnings date
31/08/2024
As of date
23/04/2026
Close
16.57
Open
16.69
High
17.08
Low
16.36
Nurix Therapeutics Inc. a clinical stage biopharmaceutical company focuses on the discovery development and commercialization of small molecule and cell therapies for the treatment of cancer and other diseases. The company develops NX-2127 an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948 an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607 an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing DeTIL-0255 a drug-enhanced investigational cell therapy product that uses NX-0255 ex vivo to enhance tumor infiltrating lymphocytes propagation and phenotypic characteristics. The company has a strategic collaboration agreement with Gilead Sciences Inc. to discover develop and commercialize a pipeline of protein degradation drugs for patients with cancer and other challenging diseases; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco California.
View LessNRIX | US
Risk
52.2
Sharpe
0.63
Luna's Score
42/100
Recommendation
Sell
Luna says (NRIX | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
What's not Working
Price Below SMA10D
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
46.6%1 month
52.2%3 months
48.7%6 months
62.4%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
4.65
Debt to equity
0.07
Debt to assets
0.05
Ent. to EBITDA
-3.35
Ent. to rev.
23.57
PEG
-
Other Fundamentals
EBITDA
-186.40M
MarketCap
1.17B
MarketCap(USD)
1.17B
Div. yield
-
Op. margin
-433.83
Erngs. growth
-
Rev. growth
-31.80
Ret. on equity
-57.96
Short ratio
15.25
Short perc.
15.23
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
2.21
Range1M
3.67
Range3M
6.17
Volumes: Market Activity
Rel. volume
0.73
Price X volume
14.62M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -3.35 | - | Cheaper |
| Ent. to Revenue | 23.57 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 4.65 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 48.70 | - | Lower Risk |
| Debt to Equity | 0.07 | -1.23 | Expensive |
| Debt to Assets | 0.05 | 0.25 | Cheaper |
| Market Cap | 1.17B | - | Emerging |
